Sanofi India Ltd
Company Profile
Business description
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and other export markets.
Contact
Saki Vihar Road
Sanofi House, CTS Number 117-B
L&T Business Park
Powai
MumbaiMH400072
INDT: +91 2228032000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
1,285
Stocks News & Analysis
stocks
Distribution growth for ASX income play
stocks
We take a different view to market on ASX bloodbath
stocks
BHP earnings weaker with lower iron ore prices more than offsetting higher copper volumes
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,177.40 | 3.60 | 0.04% |
CAC 40 | 7,973.03 | 6.05 | -0.08% |
DAX 40 | 24,276.97 | 146.10 | -0.60% |
Dow JONES (US) | 44,897.34 | 24.93 | -0.06% |
FTSE 100 | 9,288.14 | 98.92 | 1.08% |
HKSE | 25,165.94 | 43.04 | 0.17% |
NASDAQ | 21,107.28 | 207.68 | -0.97% |
Nikkei 225 | 42,888.55 | 657.74 | -1.51% |
NZX 50 Index | 13,071.30 | 142.62 | 1.10% |
S&P 500 | 6,382.91 | 28.46 | -0.44% |
S&P/ASX 200 | 8,918.00 | 21.80 | 0.25% |
SSE Composite Index | 3,766.21 | 38.92 | 1.04% |